Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tenecteplase vs Alteplase and Time to Treatment for Acute Ischemic Stroke.

JAMA network open·2026
Same author

P2Y12 Inhibitors and Mortality in Patients Hospitalized With Intracerebral Hemorrhage.

JAMA network open·2026
Same author

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.

BMJ open·2026
Same author

Authors' Reply to the Letter by Dr. Toshikuni on Endotype Clustering, Hepatic Steatosis, and Vulnerable Coronary Plaque.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Rural-Urban Disparity in Postacute Care and 1-Year Outcomes After Ischemic Stroke.

Stroke·2026
Same author

Artificial intelligence denoising in cardiac photon-counting CT: mitigating BMI-related noise degradation while maintaining clinical interchangeability.

European journal of radiology·2026

Related Experiment Video

Updated: May 23, 2026

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells
09:15

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

Hepatic Steatosis Is Associated With Increased Cardiovascular Risk Through Adverse Coronary Plaque Composition.

Jan M Brendel1, Thomas Mayrhofer2, Nóra M Kerkovits3

  • 1Department of Radiology, Cardiovascular Imaging Research Center (CIRC), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Radiology, University of Tuebingen, Tuebingen, Germany.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|May 21, 2026
PubMed
Summary

Hepatic steatosis (fatty liver disease) is linked to a higher risk of major adverse cardiovascular events (MACE). This risk is partly explained by increased noncalcified plaque burden in coronary arteries, suggesting vulnerable atherosclerosis.

Keywords:
Coronary Computed Tomography AngiographyHepatic SteatosisMajor Adverse Cardiovascular EventsOutcomesRisk Stratification

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Related Experiment Videos

Last Updated: May 23, 2026

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells
09:15

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Area of Science:

  • Cardiology
  • Radiology
  • Hepatology

Background:

  • Hepatic steatosis is independently linked to major adverse cardiovascular events (MACE).
  • The precise relationship between hepatic steatosis, coronary plaque characteristics, and MACE remains incompletely understood.
  • Understanding this link is crucial for cardiovascular risk stratification.

Purpose of the Study:

  • To investigate the association between hepatic steatosis and coronary plaque composition.
  • To determine if hepatic steatosis predicts MACE independently of traditional risk factors and plaque burden.
  • To explore the mediating role of coronary plaque characteristics in the hepatic steatosis-MACE relationship.

Main Methods:

  • Analysis of 3,637 patients from the PROMISE trial randomized to the CT arm.
  • Hepatic steatosis assessed via non-contrast CT using hepatic and splenic attenuation.
  • Coronary CT angiography quantified plaque volume and burden; multivariable regression and mediation analyses assessed outcomes.

Main Results:

  • 25.5% of patients had hepatic steatosis, associated with higher MACE rates.
  • Hepatic steatosis correlated with greater noncalcified plaque burden (NCPB) after risk factor adjustment.
  • Hepatic steatosis independently predicted increased MACE risk, with NCPB mediating 11% of this association.

Conclusions:

  • Hepatic steatosis is associated with increased noncalcified plaque burden and MACE risk.
  • Noncalcified plaque burden partially mediates the relationship between hepatic steatosis and MACE.
  • Findings suggest a link between hepatic steatosis and vulnerable coronary atherosclerosis, supporting integrated cardiometabolic risk assessment.